Filing identity and reporting period
Important metadata discrepancy: The supplied filing is Isoray, Inc.’s Form 10-K, not a Perspective Therapeutics filing. It reports the fiscal year ended June 30, 2022 (FY2022), was signed September 28, 2022, and includes FY2022 fourth-quarter results. It is not a 2021 Q4 report. Isoray’s core business was manufacturing and selling Cesium-131 brachytherapy products for cancer treatment.
Key financial results
Amounts are in U.S. dollars; financial statement figures below are in millions unless noted. The filing presents one operating segment.
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Net sales | $10.795 | $10.053 | Up 7% |
| Gross profit / margin | $4.616 / 42.8% | $5.121 / 50.9% | Margin down 8.1 percentage points |
| Operating expenses | $12.007 | $8.567 | Up 40% |
| Operating loss | $(7.391) | $(3.446) | Loss widened |
| Net loss | $(7.272) | $(3.387) | Loss widened |
| Basic and diluted loss per share | $(0.05) | $(0.03) | |
| Cash used in operating activities | $(7.710) | $(2.837) | Use increased |
FY2022 sales growth reflected a 23% increase in “other” applications, particularly brain cancer and GammaTile-related sales, and price increases; prostate sales rose about 3%. Prostate brachytherapy remained 75% of revenue. Increased labor, isotope and freight costs, unused isotope, and depreciation contributed to higher cost of sales and lower gross margin. R&D expense rose to $2.582 million from $1.427 million; general and administrative expense rose to $6.621 million from $4.691 million.
For FY2022 Q4, net revenue was $2.505 million, gross profit $0.926 million, and net loss $2.078 million. The comparable FY2021 Q4 figures were $2.710 million, $1.346 million, and $1.061 million, respectively.
Liquidity, debt and cash flow
At June 30, 2022, cash and cash equivalents were $55.890 million (plus $0.182 million restricted cash), versus $63.828 million a year earlier. Working capital was $57.063 million and the current ratio was 26.18. Total liabilities were $3.162 million, including lease liabilities and an asset retirement obligation; the filing reports no borrowings or other debt. Cash declined by $7.938 million during FY2022. Investing cash use was $0.284 million and financing provided $0.056 million. Inventory increased, including $2.269 million of non-current enriched barium inventory intended for Cesium-131 production.
Outlook, material developments and risks
- Management said existing cash was expected to fund projected operating needs for the next 12 months. It targeted 25% revenue growth in FY2023; if that growth target and continued growth were achieved, management estimated cash-flow break-even in three to four years. These are expectations, not assurances.
- Cesium-131 supply was concentrated in Russian reactors. A reactor outage temporarily halted customer shipments from mid-August to early September 2022; regular shipping resumed by September 7. The company had not received isotope from a domestic supplier since January 2019 and did not expect a new reactor source online in FY2023.
- Customer concentration was significant: the largest physician-practice/facility group represented 27.9% of FY2022 sales, GT Medical Technologies 14.2%, and another customer about 6.3%. GT sales exceeded 10% of revenue in FY2021 and FY2022.
- On September 27, 2022, Isoray agreed to acquire Viewpoint Molecular Targeting in an all-stock merger. Viewpoint shareholders would own 49% of the combined company on a fully diluted basis. Closing remained subject to approvals and other conditions. The filing also disclosed the medical director’s resignation notice on September 20, 2022.
- COVID-19 effects, hospital staffing constraints, competition, reimbursement uncertainty and reliance on a single product remained risks. The company reported no legal proceedings to disclose. The auditor issued an unqualified opinion and identified no critical audit matters; management said disclosure controls and internal control over financial reporting were effective.
Important facts for investors to verify
- Confirm the issuer and period: this is Isoray’s FY2022 10-K, not Perspective Therapeutics’ 2021 Q4 filing.
- Review the full audited statements and notes, particularly operating cash use, inventory valuation and the enriched-barium supply arrangements.
- Assess whether management’s FY2023 25% sales-growth target and cash runway assumptions remain achievable given losses, margin compression and Russian isotope dependence.
- Check the status and final terms of the Viewpoint merger, including approvals, dilution and integration plans.
- Track customer concentration, the medical director’s departure, GammaTile sales, and reimbursement and market adoption trends.